Why Flerie stock moves
Flerie rose slightly.
Written after the close on ·
Why today
16,413 news analyzed todayFlerie rose slightly.
Flerie rose, against a falling market after a rights issue at its portfolio company Xspray Pharma.
Over the last five trading days Flerie fell very sharply while OMX Stockholm 30 was roughly flat, a very big move for the stock.
The rights issue, worth about SEK 90 million, lets existing shareholders buy new shares, which can weigh on a share price.
Flerie's own net asset value per share fell 3.3% in October, adding to the pressure.
Today's move of +0.39% was 0.5 times a normal day's 0.9%. OMX Stockholm 30 moved −1.01% on the same day.
Flerie +0.39%OMX Stockholm 30 −1.01%Against the market
What analysts expect, and how often they have been right
Analysts’ estimates for Flerie.
Ratings
Price targets
Latest price 12.80 SEK
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. October 23: Buy about 160 thousand SEK. October 21: Buy about 140 thousand SEK. October 19: Buy about 147 thousand SEK. October 16: Buy about 144 thousand SEK. April 28: Buy about 149 thousand SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 2 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −20% and earnings per share went from -2.83 SEK to -8.50 SEK.
Revenue, profit and market cap
RevenueProfitMarket capbn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 2 out of 3 years.Market cap (Now): 1.1 bn SEKRevenue 2025: 0.0 m SEK
What the key figures say about Flerie
The figures connect what Flerie earns with what investors pay.
The line shows the share price in the same year, on its own scale.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -16.62 SEK–-2.83 SEK. Peers: Oncopeptides -0.76 SEK, AlzeCure Pharma 0.30 SEK, Pyxis Oncology -$1.27.
What the company sold during the year.
2022–2025: 0.0 m SEK–0.1 m SEK. Peers: Oncopeptides 104 m SEK, AlzeCure Pharma 97.3 m SEK, Pyxis Oncology $11.0M.
The percentage of revenue left after the costs of running the business.
2022–2025: −105600.0%–−105600.0%. Peers: Oncopeptides −204.5%, AlzeCure Pharma 31.3%, Pyxis Oncology −834.4%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −30.0%–−5.4%. Peers: AlzeCure Pharma 62.9%, Pyxis Oncology −179.1%.
What investors pay for each unit the company sells.
2022–2025: 36,652.18–36,652.18. Peers: Oncopeptides 7.27, AlzeCure Pharma 7.23, Pyxis Oncology 17.99.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 0.04–1.35. Peers: AlzeCure Pharma 9.23, Pyxis Oncology 1.95.
Cash left after investments, divided by the number of shares.
2022–2025: -21.26 SEK–-0.19 SEK. Peers: Oncopeptides -0.42 SEK, AlzeCure Pharma -0.46 SEK, Pyxis Oncology -$0.57.
The percentage of assets financed by shareholders’ equity.
2022–2025: 95.1%–99.5%.
What followed similar falls?
Including reinvested dividends, Flerie fell 7.9% over the latest five trading days. Since November 7, 2016, falls at least this large were followed by a higher value 21 trading days later in 15 out of 37 non-overlapping periods. The median was −1.3%, against −2.2% for an ordinary 21-day period, which ended higher 41 times in 100.
Such a fall has not said much about the next month.
−1.3% · 15/37
What to watch next, and why
The earnings report shows how Flerie's revenue and profit have changed.
- Earnings report
The earnings report shows how Flerie's revenue and profit have changed.
Add to calendar
More about Flerie
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- Mark Quick, senior executiveBuyabout 160 thousand SEK
- Ted Fjällman, CEO (closely associated)Buyabout 140 thousand SEK
- Ted Fjällman, CEO (closely associated)Buyabout 147 thousand SEK
- Ted Fjällman, CEO (closely associated)Buyabout 144 thousand SEK
- Mark Quick, senior executiveBuyabout 149 thousand SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 16 report days Flerie usually moved about 0.9%. On a normal day it moves 0.9%.
−0.63% +0.00% −4.18% −0.14%
10,000 SEK in Flerie bought on November 7, 2016 is worth 650 SEK today, with dividends reinvested.
What would 10,000 SEK in Flerie be worth today? →
What would 10,000 SEK in Flerie be worth today?
650 SEK
with dividends reinvested, bought on November 7, 2016.
At worst it was worth 648 SEK (November 5, 2026).
The five biggest days of the journey
· −64.8% · the whole market rose 0.7% the same day
· +52.1% · the whole market rose 0.8% the same day
· −26.8% · the whole market rose 0.3% the same day
· −22.7% · the whole market fell 0.3% the same day · report day
· +17.4% · the whole market was unchanged the same day
Earlier days
−7.91% market −0.11% Flerie fell very sharply over the week, while the broader Stockholm market was roughly flat. Read →
Flerie fell very sharply over the week, while the broader Stockholm market was roughly flat.
A rights issue means existing shareholders are offered new shares, which can weigh on the price of the existing shares.
The move was large by Flerie's standards, and the share price is now near its lowest close of the past year.
Flerie's next report is due on Wednesday 20 January 2027.
−1.92% market −0.32% Flerie fell sharply without a company-news explanation. Read →
Flerie fell sharply without a company-news explanation.
Flerie fell sharply while OMX Stockholm 30 fell only slightly, so it moved more than the market.
Over the last five trading days Flerie fell very sharply while OMX Stockholm 30 rose slightly, a very big move for the stock.
The latest close sits near the lowest level of the past year, well below its highest close last year.
The next earnings report is due Wednesday 20 January 2027.
−1.89% market +0.83% Flerie fell, moving against a slightly rising market. Read →
Flerie fell, moving against a slightly rising market.
The Life Science investor's net asset value per share fell 3.3% in October, to 34.72 SEK, which pressured the share price.
Over five days the stock fell very sharply, a very big move for Flerie, roughly four times a normal five-day stretch.
Trading was around its usual level.
Investors likely reacted to the lower asset value, shares issued in the Biosergen merger, and a fall in the share price toward its lowest close of the past year.
−2.57% market −0.08% Flerie fell sharply. Read →
Flerie fell sharply.
Its net asset value per share fell 3.3% in October, to 34.72 SEK.
The rest of the week also saw a large decline, against a slightly rising market.
Likely the NAV drop, a value of holdings.
Trading was well above its usual level, and the share sits at its lowest close of the past year.
−2.16% market +0.48% Flerie fell sharply while the market rose slightly. Read →
Flerie fell sharply while the market rose slightly.
No company news from that session explains the move.
Over the last five trading days Flerie fell very sharply, against a clearly rising market.
That is a very big move for Flerie, and such moves have been rare over the past year.
Earlier news from the merger with Biosergen and a planned share issue may add to selling pressure.
−3.14% market −0.29% Flerie fell sharply without a company-news explanation. Read →
Flerie fell sharply without a company-news explanation.
Over the last five trading days, Flerie fell very sharply while the OMX Stockholm 30 rose clearly, so it moved against the market.
In the last session it fell very sharply, a bigger drop than the market's slight decline.
Earlier news covered the completed Biosergen merger and a planned rights issue by its portfolio company Nanologica, but neither was announced in that session.
−8.55% market +3.01% Flerie fell very sharply over the week, moving against a market that rose clearly. Read →
Flerie fell very sharply over the week, moving against a market that rose clearly.
The move was very big for the company, about four times a normal five-day stretch, and the share price sits at its lowest close of the past year.
The likeliest driver is the completed merger with Biosergen, which added 2.67 million new shares as payment, so the share count grew.
Its portfolio company Nanologica also named Mark Quick as CEO and announced a rights issue of about SEK 110.5 million, which likely weighed on sentiment.
−3.38% market +0.33% Flerie fell, while OMX Stockholm 30 rose slightly. Read →
Flerie fell, while OMX Stockholm 30 rose slightly.
No company news explains this move.
Over the last five trading days Flerie fell sharply, against a slightly rising market.
The drop came on heavy trading, and the latest close sits near the lowest level of the past year.
The most likely driver is the completed merger with Biosergen, partly alongside a planned rights issue, a share sale to existing shareholders.
−1.97% market +1.57% Flerie fell sharply, while the market rose clearly. Read →
Flerie fell sharply, while the market rose clearly.
Completion of the Biosergen merger was announced that day, and it is the most likely reason.
The merger added 2.67 million new shares, which can weigh on existing holders.
Over the last five trading days Flerie fell slightly, a little less than the market.
−2.56% market +1.25% Flerie fell sharply as the market rose, most likely because of the merger news: the Swedish Companies Registration Office approved the merger plan with Biosergen, a company the Stockholm-listed shareholder company folds into itself, and Biosergen is set to be delisted. Read →
Flerie fell sharply as the market rose, most likely because of the merger news: the Swedish Companies Registration Office approved the merger plan with Biosergen, a company the Stockholm-listed shareholder company folds into itself, and Biosergen is set to be delisted.
Such mergers can add dilution and integration uncertainty for holders, and the drop also followed the company's weak quarterly report, which showed a lower net asset value per share (the value of its stakes in other companies, divided by its share count) and a full writedown of Empros Pharma.
Over the last five trading days, Flerie was roughly flat while OMX Stockholm 30 rose slightly.
Next to watch is the merger registration, expected on October 23, 2026.
+0.33% market +1.19% Flerie was roughly unchanged over the last five trading days, moving less than the broader market, which rose slightly. Read →
Flerie was roughly unchanged over the last five trading days, moving less than the broader market, which rose slightly.
The main company news was the approval from the Swedish Companies Registration Office for its merger with Biosergen, which is a structural step rather than a value-changing event, so it likely had limited price impact.
The company also published its Q3 2026 interim report yesterday, showing net asset value per share down about 8 per cent in the quarter, driven by write-downs in portfolio companies, which likely weighed on sentiment.
Net asset value is the estimated value of the company's holdings minus its debts, divided by the number of shares.
Learn more · Why do stocks go up and down?